Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 5/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721147 | 1.00 | ALDH1A1 (0.58) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL262657 | 1.00 | ALDH1A1 (0.58) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL2418959 | 0.94 | TSHR (0.60) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL2418958 | 0.94 | TSHR (0.60) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL10602340 | 0.94 | TSHR (0.60) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL23931119 | 0.92 | ALDH1A1 (0.50) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL10602355 | 0.92 | TSHR (0.63) | ALDH1A1ATMTSHRHCAR2NAAA | |
| SCHEMBL4147264 | 0.92 | TSHR (0.63) | ALDH1A1ATMTSHRHCAR2NAAA | |
| SCHEMBL10607403 | 0.92 | TSHR (0.63) | ALDH1A1ATMTSHRHCAR2NAAA | |
| SCHEMBL1831155 | 0.92 | TSHR (0.63) | ALDH1A1ATMTSHRHCAR2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013149323-A1 | NATURAL PRODUCTS FOR SKIN CARE | NTEGRITY (CA) | 2013-10-10 | — | — | WO | claimed |
| US-20090246278-A1 | USE OF ESSENTIAL OILS TO REDUCE BENZODIAZEPINE REQUIREMENTS DURING MEDICAL PROCEDURES | HEDAYAT KAMYAR MALEK | 2009-10-01 | — | — | US | claimed |
| US-12552129-B2 | Nonwoven water-soluble composite structure | MONOSOL, LLC (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260027136-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | YUZU LV LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12478575-B2 | Stable perfuming compositions having good spray properties | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES—SEPPIC (FR) | 2025-11-25 | — | — | US | disclosed |
| US-12458653-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2025-11-04 | — | — | US | disclosed |
| US-12427176-B2 | Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products | RIZUN NODARI (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4382083-B1 | NONWOVEN WATER-SOLUBLE COMPOSITE STRUCTURE | MONOSOL LLC (US) | 2025-06-25 | — | — | EP | disclosed |
| WO-2025123127-A1 | TOPICAL COMPOSITION AND USE THEREOF TO REDUCE POST-SURGICAL USE OF OPIOIDS | KAZM PHARMACEUTICALS INC. (CA) | 2025-06-19 | — | — | WO | disclosed |
| US-12303488-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2025-05-20 | — | — | US | disclosed |
| US-8147808-B2 | Consumer noticeable improvement in wetness protection using solid antiperspirant compositions | THE PROCTER & GAMBLE COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| WO-2012039516-A1 | DEODORANT COMPOSITION FOR SULFIDES | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-03-29 | — | — | WO | disclosed |
| US-20090246278-A1 | USE OF ESSENTIAL OILS TO REDUCE BENZODIAZEPINE REQUIREMENTS DURING MEDICAL PROCEDURES | HEDAYAT KAMYAR MALEK | 2009-10-01 | — | — | US | disclosed |
| US-20090087401-A1 | DEODORANT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-04-02 | — | — | US | disclosed |
| US-20080085251-A1 | even at a neutral to weakly acidic pH; a lactone or lactam having a mercapto group; with thioglycolic acid, thiolactic acid, cysteine, acetylcysteine, cysteamine, acylcysteamine; | RESONAC CORPORATION (JP) | 2008-04-10 | — | — | US | disclosed |
| EP-1827370-A1 | HAIR PROCESSING AGENT AND METHOD FOR PERMANENT WAVING HAIR | Showa Denko K.K. (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060165622-A1 | Deodorant composition | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-07-27 | — | — | US | disclosed |
| WO-2006068276-A1 | HAIR PROCESSING AGENT AND METHOD FOR PERMANENT WAVING HAIR | SHOWA DENKO K.K. (JP) | 2006-06-29 | — | — | WO | disclosed |
| EP-1561476-A1 | DEODORANT COMPOSITION | Takasago International Corporation (JP) | 2005-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12478575-B2 | Stable perfuming compositions having good spray properties | PARG, PLG, POLG | ALDH1A1 3553/4885ATM 3225/4885TSHR 4809/4885 |
| US-12552129-B2 | Nonwoven water-soluble composite structure | SMARCD2, BRWD1, PWWP2B | ALDH1A1 2189/4885ATM 494/4885TSHR 4022/4885 |
| US-20260027136-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | CNR1, CNR2, OPRM1 | ALDH1A1 1420/4885ATM 3517/4885TSHR 4394/4885 |
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | TRPV1, SOST, RUNX1 | ALDH1A1 4768/4885ATM 2546/4885TSHR 3626/4885 |
| US-20080085251-A1 | even at a neutral to weakly acidic pH; a lactone or lactam having a mercapto group; with thioglycolic acid, thiolactic acid, cysteine, acetylcysteine, cysteamine, acylcysteamine; | TST, CYSLTR1, CYSLTR2 | ALDH1A1 672/4885ATM 1747/4885TSHR 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.